Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yingjuan J. Lu"'
Autor:
Yingjuan J. Lu, Leroy W. Wheeler, II, Haiyan Chu, Paul J. Kleindl, Michael Pugh, Fei You, Satish Rao, Gabriela Garcia, Henry Y. Wu, Andre P. da Cunha, Richard Johnson, Elaine Westrick, Vicky Cross, Alex Lloyd, Christina Dircksen, Patrick J. Klein, Iontcho R. Vlahov, Philip S. Low, Christopher P. Leamon
Publikováno v:
Cell Reports Medicine, Vol 2, Iss 10, Pp 100422- (2021)
Summary: Provoked by sterile/nonsterile insults, prolonged monocyte mobilization and uncontrolled monocyte/macrophage activation can pose imminent or impending harm to the affected organs. Curiously, folate receptor beta (FRβ), with subnanomolar aff
Externí odkaz:
https://doaj.org/article/e2fda03da1f14baea081c09735a4dc68
Autor:
Gabriela E. Garcia, Yingjuan J. Lu, Luan D. Truong, Carlos A. Roncal-Jiménez, Makoto Miyazaki, Shinobu Miyazaki-Anzai, Gabriel Cara-Fuentes, Ana Andres-Hernando, Miguel Lanaspa, Richard J. Johnson, Christopher P. Leamon
Publikováno v:
Cells, Vol 10, Iss 8, p 2113 (2021)
Since activated macrophages express a functional folate receptor β (FRβ), targeting this macrophage population with folate-linked drugs could increase selectivity to treat inflammatory diseases. Using a macrophage-mediated anti-glomerular basement
Externí odkaz:
https://doaj.org/article/a237aed524fc4da6a846bffd9ae6a3dd
Autor:
Yingjuan J. Lu, Haiyan Chu, Leroy W. Wheeler, Melissa Nelson, Elaine Westrick, James F. Matthaei, Ian I. Cardle, Adam Johnson, Joshua Gustafson, Nikki Parker, Marilynn Vetzel, Le-Cun Xu, Emilia Z. Wang, Michael C. Jensen, Patrick J. Klein, Philip S. Low, Christopher P. Leamon
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Chimeric antigen receptor (CAR)-T cell therapy has transformed pediatric oncology by producing high remission rates and potent effects in CD19+ B-cell malignancies. This scenario is ideal as CD19 expression is homogeneous and human blood provides a f
Externí odkaz:
https://doaj.org/article/25853ddcfde5498d880a46edf8747200
Autor:
Philip S. Low, Paul J. Kleindl, Andre P. da Cunha, Satish Rao, Patrick J. Klein, Leroy W Wheeler, Henry Y. Wu, Christopher P. Leamon, Yingjuan J. Lu, Fei You, Alex Lloyd, Christina Dircksen, Chu Haiyan, Michael Pugh, Gabriela E. Garcia, Vicky Cross, Elaine Westrick, Richard J. Johnson, Iontcho R. Vlahov
Publikováno v:
Cell Reports Medicine, Vol 2, Iss 10, Pp 100422-(2021)
Cell Reports Medicine
Cell Reports Medicine
Summary Provoked by sterile/nonsterile insults, prolonged monocyte mobilization and uncontrolled monocyte/macrophage activation can pose imminent or impending harm to the affected organs. Curiously, folate receptor beta (FRβ), with subnanomolar affi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ff3f0adb683c62473135f1023e5e206
http://www.sciencedirect.com/science/article/pii/S2666379121002846
http://www.sciencedirect.com/science/article/pii/S2666379121002846
Autor:
Ana Andres-Hernando, Miguel A. Lanaspa, Shinobu Miyazaki-Anzai, Yingjuan J. Lu, Christopher P. Leamon, Gabriela E. Garcia, Luan D. Truong, Gabriel Cara-Fuentes, Richard J. Johnson, Carlos A. Roncal-Jimenez, Makoto Miyazaki
Publikováno v:
Cells
Volume 10
Issue 8
Cells, Vol 10, Iss 2113, p 2113 (2021)
Volume 10
Issue 8
Cells, Vol 10, Iss 2113, p 2113 (2021)
Since activated macrophages express a functional folate receptor β (FRβ), targeting this macrophage population with folate-linked drugs could increase selectivity to treat inflammatory diseases. Using a macrophage-mediated anti-glomerular basement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f5e040ae974605d0927917b7c552ee7
Autor:
Joshua A. Gustafson, Adam Johnson, Patrick J. Klein, Christopher P. Leamon, Ian I. Cardle, Philip S. Low, Melissa Nelson, Nikki Parker, Yingjuan J. Lu, Marilynn Vetzel, Le-Cun Xu, Matthaei James, Elaine Westrick, Leroy W. Wheeler, Emilia Z. Wang, Haiyan Chu, Michael C. Jensen
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 9 (2019)
Frontiers in Oncology, Vol 9 (2019)
Chimeric antigen receptor (CAR)-T cell therapy has transformed pediatric oncology by producing high remission rates and potent effects in CD19+ B-cell malignancies. This scenario is ideal as CD19 expression is homogeneous and human blood provides a f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f550c5fe33194fd6fcc376e550b8cce
https://doi.org/10.3389/fonc.2019.00151
https://doi.org/10.3389/fonc.2019.00151